A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years.
Interleukin-6 overproduction is pathologically involved in adult onset Still's disease (AOSD). We successfully treated a man with refractory AOSD utilizing tocilizumab. Tocilizumab was discontinued after 15 doses due to intestinal bleeding, but the efficacy was sustained over 21 months. Tocilizumab was readministered safely upon recurrence and showed similar efficacy over 6 years. Corticosteroid and NSAIDs could be discontinued and intestinal bleeding was no more observed. Tocilizumab can be a therapeutic option for AOSD.
Nakahara
Hideko
H
Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Mima
Toru
T
Yoshio-Hoshino
Naoko
N
Matsushita
Masato
M
Hashimoto
Jun
J
Nishimoto
Norihiro
N